Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan

Nicolo' Gebbia, Antonio Russo, Maria Rosaria Valerio, Laura Rocci, Fabrizio Battistoni, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini, Michele Gavasci, Giordano Dicuonzo

Risultato della ricerca: Article

34 Citazioni (Scopus)

Abstract

OBJECTIVE: We designed this trial to investigate if modifications in levels of circulating vascular endothelial growth factor (VEGF) may be related to clinical response and outcome in advanced colorectal cancer patients during treatment with a weekly combination of cetuximab plus irinotecan. METHODS: A total of 45 heavily pretreated metastatic colorectal cancer patients were prospectively evaluated for circulating levels of VEGF during the treatment with cetuximab plus weekly irinotecan. VEGF circulating levels were assessed at the following time points: just before and at 1, 21, 50 and 92 days after the start of cetuximab plus irinotecan treatment. RESULTS: Basal VEGF median levels were significantly decreased just 1 day after the first anticancer infusion (p = 0.016) and reached the highest statistical significance 92 days after the first infusion (p < 0.0001). A total of 22 patients showed a reduction in median VEGF circulating levels of at least 50% 92 days after the first infusion with respect to the basal time point. For patients with at least a 50% reduction in VEGF levels, the response rate was 45.5% compared with 8.7% in the nonreduced VEGF group (p = 0.014). The median time to progression was 6 months in the reduced VEGF group versus 3.9 months in the other patients (p < 0.0001). In addition, overall survival was longer in patients with VEGF reduction (11.0 months) than in patients without (9.6 months; p = 0.01). CONCLUSION: These data represent the first evidence that suggests a role of VEGF reduction in the prediction of efficacy of treatment with cetuximab plus weekly irinotecan in heavily pretreated advanced colorectal cancer patients.
Lingua originaleEnglish
pagine (da-a)319-327
Numero di pagine9
RivistaPharmacogenomics
Volume8
Stato di pubblicazionePublished - 2007

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Genetics

Cita questo

Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. / Gebbia, Nicolo'; Russo, Antonio; Valerio, Maria Rosaria; Rocci, Laura; Battistoni, Fabrizio; Vincenzi, Bruno; Tonini, Giuseppe; Santini, Daniele; Gavasci, Michele; Dicuonzo, Giordano.

In: Pharmacogenomics, Vol. 8, 2007, pag. 319-327.

Risultato della ricerca: Article

Gebbia, N, Russo, A, Valerio, MR, Rocci, L, Battistoni, F, Vincenzi, B, Tonini, G, Santini, D, Gavasci, M & Dicuonzo, G 2007, 'Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan', Pharmacogenomics, vol. 8, pagg. 319-327.
Gebbia, Nicolo' ; Russo, Antonio ; Valerio, Maria Rosaria ; Rocci, Laura ; Battistoni, Fabrizio ; Vincenzi, Bruno ; Tonini, Giuseppe ; Santini, Daniele ; Gavasci, Michele ; Dicuonzo, Giordano. / Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. In: Pharmacogenomics. 2007 ; Vol. 8. pagg. 319-327.
@article{9c8564ddcbea4c87ba468dd3ef6c56e8,
title = "Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan",
abstract = "OBJECTIVE: We designed this trial to investigate if modifications in levels of circulating vascular endothelial growth factor (VEGF) may be related to clinical response and outcome in advanced colorectal cancer patients during treatment with a weekly combination of cetuximab plus irinotecan. METHODS: A total of 45 heavily pretreated metastatic colorectal cancer patients were prospectively evaluated for circulating levels of VEGF during the treatment with cetuximab plus weekly irinotecan. VEGF circulating levels were assessed at the following time points: just before and at 1, 21, 50 and 92 days after the start of cetuximab plus irinotecan treatment. RESULTS: Basal VEGF median levels were significantly decreased just 1 day after the first anticancer infusion (p = 0.016) and reached the highest statistical significance 92 days after the first infusion (p < 0.0001). A total of 22 patients showed a reduction in median VEGF circulating levels of at least 50{\%} 92 days after the first infusion with respect to the basal time point. For patients with at least a 50{\%} reduction in VEGF levels, the response rate was 45.5{\%} compared with 8.7{\%} in the nonreduced VEGF group (p = 0.014). The median time to progression was 6 months in the reduced VEGF group versus 3.9 months in the other patients (p < 0.0001). In addition, overall survival was longer in patients with VEGF reduction (11.0 months) than in patients without (9.6 months; p = 0.01). CONCLUSION: These data represent the first evidence that suggests a role of VEGF reduction in the prediction of efficacy of treatment with cetuximab plus weekly irinotecan in heavily pretreated advanced colorectal cancer patients.",
author = "Nicolo' Gebbia and Antonio Russo and Valerio, {Maria Rosaria} and Laura Rocci and Fabrizio Battistoni and Bruno Vincenzi and Giuseppe Tonini and Daniele Santini and Michele Gavasci and Giordano Dicuonzo",
year = "2007",
language = "English",
volume = "8",
pages = "319--327",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",

}

TY - JOUR

T1 - Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan

AU - Gebbia, Nicolo'

AU - Russo, Antonio

AU - Valerio, Maria Rosaria

AU - Rocci, Laura

AU - Battistoni, Fabrizio

AU - Vincenzi, Bruno

AU - Tonini, Giuseppe

AU - Santini, Daniele

AU - Gavasci, Michele

AU - Dicuonzo, Giordano

PY - 2007

Y1 - 2007

N2 - OBJECTIVE: We designed this trial to investigate if modifications in levels of circulating vascular endothelial growth factor (VEGF) may be related to clinical response and outcome in advanced colorectal cancer patients during treatment with a weekly combination of cetuximab plus irinotecan. METHODS: A total of 45 heavily pretreated metastatic colorectal cancer patients were prospectively evaluated for circulating levels of VEGF during the treatment with cetuximab plus weekly irinotecan. VEGF circulating levels were assessed at the following time points: just before and at 1, 21, 50 and 92 days after the start of cetuximab plus irinotecan treatment. RESULTS: Basal VEGF median levels were significantly decreased just 1 day after the first anticancer infusion (p = 0.016) and reached the highest statistical significance 92 days after the first infusion (p < 0.0001). A total of 22 patients showed a reduction in median VEGF circulating levels of at least 50% 92 days after the first infusion with respect to the basal time point. For patients with at least a 50% reduction in VEGF levels, the response rate was 45.5% compared with 8.7% in the nonreduced VEGF group (p = 0.014). The median time to progression was 6 months in the reduced VEGF group versus 3.9 months in the other patients (p < 0.0001). In addition, overall survival was longer in patients with VEGF reduction (11.0 months) than in patients without (9.6 months; p = 0.01). CONCLUSION: These data represent the first evidence that suggests a role of VEGF reduction in the prediction of efficacy of treatment with cetuximab plus weekly irinotecan in heavily pretreated advanced colorectal cancer patients.

AB - OBJECTIVE: We designed this trial to investigate if modifications in levels of circulating vascular endothelial growth factor (VEGF) may be related to clinical response and outcome in advanced colorectal cancer patients during treatment with a weekly combination of cetuximab plus irinotecan. METHODS: A total of 45 heavily pretreated metastatic colorectal cancer patients were prospectively evaluated for circulating levels of VEGF during the treatment with cetuximab plus weekly irinotecan. VEGF circulating levels were assessed at the following time points: just before and at 1, 21, 50 and 92 days after the start of cetuximab plus irinotecan treatment. RESULTS: Basal VEGF median levels were significantly decreased just 1 day after the first anticancer infusion (p = 0.016) and reached the highest statistical significance 92 days after the first infusion (p < 0.0001). A total of 22 patients showed a reduction in median VEGF circulating levels of at least 50% 92 days after the first infusion with respect to the basal time point. For patients with at least a 50% reduction in VEGF levels, the response rate was 45.5% compared with 8.7% in the nonreduced VEGF group (p = 0.014). The median time to progression was 6 months in the reduced VEGF group versus 3.9 months in the other patients (p < 0.0001). In addition, overall survival was longer in patients with VEGF reduction (11.0 months) than in patients without (9.6 months; p = 0.01). CONCLUSION: These data represent the first evidence that suggests a role of VEGF reduction in the prediction of efficacy of treatment with cetuximab plus weekly irinotecan in heavily pretreated advanced colorectal cancer patients.

UR - http://hdl.handle.net/10447/20340

M3 - Article

VL - 8

SP - 319

EP - 327

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

ER -